{
    "Trade/Device Name(s)": [
        "Actim PROM",
        "Actim PROM Controls"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K123986",
    "Predicate Device Reference 510(k) Number(s)": [
        "K061886"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "OAM"
    ],
    "Summary Letter Date": "December 23, 2013",
    "Summary Letter Received Date": "December 24, 2013",
    "Submission Date": "January 7, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.1550"
    ],
    "Regulation Name(s)": [
        "Urinary pH (nonquantitative) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "IGFBP-1"
    ],
    "Specimen Type(s)": [
        "Cervicovaginal secretions",
        "Vaginal swab"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay",
        "Qualitative immunoassay"
    ],
    "Methodologies": [
        "Visual interpretation"
    ],
    "Submission Type(s)": [
        "Test",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Actim PROM rapid qualitative immunoassay to detect amniotic fluid (IGFBP-1) in cervicovaginal secretions for diagnosis of rupture of fetal membranes in pregnant women \u226529 weeks gestation.",
    "Indications for Use Summary": "Visually interpreted rapid immunoassay for detecting amniotic fluid in cervicovaginal secretions, aiding diagnosis of rupture of fetal membranes in pregnant women \u226529 weeks gestation with suggestive signs, symptoms, or complaints.",
    "fda_folder": "Clinical Chemistry"
}